Estrella Immunopharma Overview
Latest ROE for Estrella Immunopharma: 251.43% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow251.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Estrella Immunopharma's return on equity stands at 251.43%. That is above the sector sector average of -4.47%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Estrella Immunopharma sits higher the its sector benchmark (-4.47%) with a ROE of 251.43%. That is roughly 5727.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 251.43% for Estrella Immunopharma means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Estrella Immunopharma's ROE evolved across reporting periods, while the comparison chart places ESLA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
